Clinical Outcome with Standard Regimen plus Clofazimine or Moxifloxacin in Cavitary Mycobacterium avium Complex Pulmonary Disease.

Yea Eun Park Young Pil ChongHyun Joo LeeTae Sun Shim Kyung Wook Jo

Published in: Antimicrobial agents and chemotherapy (2022)

In this retrospective analysis including 173 patients in a tertiary referral center in South Korea, compared with the standard therapeutic regimen, clofazimine or moxifloxacin plus standard treatment regimen potentially did not induce a higher 1-year culture conversion rate in patients with Mycobacterium avium complex pulmonary disease who present with cavitary lesions (fibrocavitary or cavitary nodular bronchiectatic type).

Keyphrases

pulmonary hypertension
end stage renal disease
mycobacterium tuberculosis
ejection fraction
newly diagnosed
chronic kidney disease
primary care
prognostic factors
patient reported outcomes
replacement therapy